TP53 Mutations are Important Predictor of Prognosis in Allo-HCT for MDS

Navneet Majhail, MD of Cleveland Clinic, discusses how TP53 mutations lead to poor overall survival in patients with MDS at the 58th ASH Annual Meeting in San Diego, CA.